TH137260B - Treatment of hot flashes, vascular scaling syndrome, and nighttime sweating with sex steroid precursors in the Combined with estrogen modulators Selectively receptors - Google Patents
Treatment of hot flashes, vascular scaling syndrome, and nighttime sweating with sex steroid precursors in the Combined with estrogen modulators Selectively receptorsInfo
- Publication number
- TH137260B TH137260B TH1101003709A TH1101003709A TH137260B TH 137260 B TH137260 B TH 137260B TH 1101003709 A TH1101003709 A TH 1101003709A TH 1101003709 A TH1101003709 A TH 1101003709A TH 137260 B TH137260 B TH 137260B
- Authority
- TH
- Thailand
- Prior art keywords
- sweating
- hot flashes
- syndrome
- nighttime
- receptors
- Prior art date
Links
- 206010060800 Hot flush Diseases 0.000 title claims abstract 3
- 208000008454 Hyperhidrosis Diseases 0.000 title claims abstract 3
- 230000035900 sweating Effects 0.000 title claims abstract 3
- 102000014961 Protein Precursors Human genes 0.000 title claims 2
- 108010078762 Protein Precursors Proteins 0.000 title claims 2
- 239000003163 gonadal steroid hormone Substances 0.000 title claims 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 title claims 2
- 201000010874 syndrome Diseases 0.000 title claims 2
- 230000002792 vascular Effects 0.000 title abstract 2
- 239000000262 estrogen Substances 0.000 title 1
- 230000000051 modifying Effects 0.000 title 1
- 238000003379 elimination reaction Methods 0.000 claims 2
- 101710011559 Drak Proteins 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N Dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 abstract 2
- 206010062060 Hyperlipidaemia Diseases 0.000 abstract 2
- 229940119350 dehydroepiandrosterone Drugs 0.000 abstract 2
- 229960002847 prasterone Drugs 0.000 abstract 2
- 206010001897 Alzheimer's disease Diseases 0.000 abstract 1
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 210000000481 Breast Anatomy 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010022489 Insulin resistance Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 210000003205 Muscles Anatomy 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 abstract 1
- 210000003905 Vulva Anatomy 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002429 anti-coagulation Effects 0.000 abstract 1
- 230000001833 anti-estrogenic Effects 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001586 eradicative Effects 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- 239000002834 estrogen receptor modulator Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 235000013372 meat Nutrition 0.000 abstract 1
- 238000005086 pumping Methods 0.000 abstract 1
- 239000000376 reactant Substances 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 210000001519 tissues Anatomy 0.000 abstract 1
Abstract
วิธีการแนวใหม่สำหรับการลดทอนให้น้อยลง หรือ การกำจัดให้หมดไปต่อ อุบัติการณ์ของอาการร้อนวูบวาบ,กลุ่มอากาศจากการปรับขนาดหลอดเลือด,และอาการเหงื่อท่วม ตัวในตอนกลางคืนในขณะเดียวกันทำการลดทอนความเสี่ยงให้น้อยลงต่อการได้มาถึงมะเร็ง เนื้อเยื่อทรวงอก,มดลูดหรือเยื่อบุมดลูกและยิ่งไปกว่านั้นจะมีผลเป็นประโยชน์ด้วยการยับยั้ง ต่อพัฒนาการของภาวะกระดูกพรุน,ภาวะมีโคเลสเตอรอลสูงในเลือด,ภาวะมีไขมันสูงในเลือด, โรคท่อเลือดแดงและหลอดเลือดแดงแข็ง,โรคความดันโลหิตสูง,ภาวะต้านทานอินซูลิน, โรคเบาหวานประเภท2,การสูบเสียมวลกล้ามเนื้อ,ภาวะเนื้อเยื่อมีไขมันมาก,โรคอัลไซเมอร์, การสูญเสียของความรูทราบ,การสูญเสียความจำหรือภาวะแห้งของช่องคลอดในสัตว์เลือดอุ่น ที่ไวรับได้อันรวมถึงมนุษย์โดยมีส่วนเกี่ยวข้องกับการดำเนินการให้ของปริมาณของสารตั้งต้น ของสเตอรอยด์ทางเพศ,โดยเฉพาะดีไฮโดรอีพิแอนโดรสเตอโรน(dehydroepiandrosterone) (DHEA)และสารต้านเอสโตรเจนหรือสารปรับคุมเอสโตรเจนรีเซปเตอร์อย่างเลือกจำเพาะ, โดยเฉพาะอย่างยิ่งสารประกอบที่มีโครงสร้างทั่วไป (สูตรเคมี) องค์ประกอบในทางเภสัชกรรมสำหรับการนำส่งส่วนประกอบออกฤทธิ์และชุดสำเร็จที่เป็น ประโยชน์ต่อการประดิษฐ์จะถูกเปิดเผยด้วยเช่นกัน.: New approaches for minimization or eradication Incidence of hot flashes, vascular scaling air groups, and sweating. In the night, while reducing the risk of developing cancer Breast tissue, anticoagulant or uterine lining and, moreover, has a beneficial effect by inhibiting On the development of osteoporosis, hypcholesterolemia, hyperlipidemia, arteriosclerosis, hypertension, insulin resistance, type 2 diabetes, pumping loss of muscle mass. Meat, hyperlipidemia, Alzheimer's disease, loss of knowledge, memory loss, or dryness of the vulva in warm-blooded animals. Sensitivity, including humans, is involved in the feeding of the reactant quantity. Of sex steroids, especially dehydroepiandrosterone (DHEA) and anti-estrogen or estrogen receptor modulators Specifically, in particular compounds with generic structures (chemical formulas), pharmaceutical elements for the delivery of active ingredients and for a The benefits to the invention will be revealed as well:
Claims (1)
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TH137260B true TH137260B (en) | 2014-10-09 |
| TH137260A TH137260A (en) | 2014-10-09 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011013689A (en) | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators. | |
| AR068702A1 (en) | PHARMACEUTICAL COMPOSITIONS | |
| HRP20191049T1 (en) | (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentalfuoromethyl)estra-4,9-dien-3-one for use in the treatment of diseases | |
| JP2013542190A5 (en) | ||
| JP2017039771A5 (en) | ||
| CU24106B1 (en) | COMPOUNDS DERIVED FROM 6,7-DIHIDRO-5H-BENZO [7] ANNULARS | |
| ME01122B (en) | Progesterone antagonists such as cdb-4124 in the treatment of breast cancer | |
| Abuohashish et al. | The ACE-2/Ang1-7/Mas cascade enhances bone structure and metabolism following angiotensin-II type 1 receptor blockade | |
| RU2017116070A (en) | METHOD FOR TREATING PRIMARY HORMONE RESISTANT ENDOMETRIAL AND BREAST CANCER | |
| BR112012002064A2 (en) | method for determining if ec145 is indicated for the treatment of a patient with an ovarian tumor or a lung tumor; method for predicting a response from an ovarian tumor or a lung tumor of a patient to ec145 therapy; method of treating platinum-resistant ovarian cancer in a patient in need; use of ec145 in combination with pegylated liposomal doxorubicin; use of ec145 for the manufacture of a medicament; method for obtaining a clinical benefit compared to treatment with a therapeutic amount of pegylated liposomal doxorubicin in the treatment of platinum-resistant ovarian cancer in a patient in need thereof; method for selecting a patient for treatment; pharmaceutical composition; dosage unit, method for determining if a patient with a tumor has functionally active folate receptors present in the patient's tumor; method of treating a folate receptor expressing epithelial tumor in a patient in need thereof; and; method for obtaining a clinical benefit in the treatment of a folate receptor-expressing epithelial tumor in a patient in need thereof | |
| Gu et al. | Micro-RNA-181a suppresses progestin-promoted breast cancer cell growth | |
| Ferreira et al. | Sex hormones differentially influence voluntary running activity, food intake and body weight in aging female and male rats | |
| JP2013500324A5 (en) | ||
| Lee et al. | (–)-Epigallocathechin-3-gallate, an AMPK activator, decreases ovariectomy-induced bone loss by suppression of bone resorption | |
| Noomhorm et al. | In vitro and in vivo effects of xanthorrhizol on human breast cancer MCF-7 cells treated with tamoxifen | |
| TH137260B (en) | Treatment of hot flashes, vascular scaling syndrome, and nighttime sweating with sex steroid precursors in the Combined with estrogen modulators Selectively receptors | |
| Lim et al. | Serum free estradiol and estrogen receptor-α mediated activity are related to decreased incident hip fractures in older women | |
| TH137260A (en) | Treatment of hot flashes, vascular scaling syndrome, and nighttime hyperhidrosis with sex steroid precursors in combination with estrogen modulators. Selectively receptors | |
| WO2009059806A3 (en) | Preparation of 6-oxa-8alpha-steroid estrogen analogues - a new group of unnatural estrogens and their use in medicine | |
| Xue et al. | Selective estrogen receptor modulator: Raloxifene | |
| Zaychenko et al. | Protective effect of vaginal resveratrol administration on joint tissues in ovariectomized rats: Targeting mTOR and сaspase 3 | |
| WO2023272407A1 (en) | Use of estretol as a treatment for endometriosis | |
| Prall | Regulation of G (1) phase progression in breast cancer cells by estrogen. | |
| Rizvi et al. | A Mouse Model of Fibrous Cholangiopathy: 282 | |
| CIG Media Group | Fulvestrant (Faslodex™, ICI 182,780) Is Active in Patients with Tamoxifen-Resistant Breast Cancer: Data from North American and European Randomized Trials |